Potency assay design for adjuvanted recombinant proteins as malaria vaccines. (Q48030992)

7 February 2018

title

Potency assay design for adjuvanted recombinant proteins as malaria vaccines. (English)

1 reference

7 February 2018

0 references

0 references

1 reference

1 reference

3

1 reference

7 February 2018

author name string

Birgitte K Giersing

1

1 reference

7 February 2018

Filip Dubovsky

2

1 reference

7 February 2018

Francoise Denamur

4

1 reference

7 February 2018

Philip Minor

5

1 reference

7 February 2018

Bruce Meade

6

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 May 2006

1 reference

7 February 2018

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

7 February 2018

volume

24

1 reference

7 February 2018

page(s)

4264-4270

1 reference

7 February 2018

issue

20

1 reference

7 February 2018

The disulfide bond structure of Plasmodium apical membrane antigen-1.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

Structural analogs of sialic acid interfere with the binding of erythrocyte binding antigen-175 to glycophorin A, an interaction crucial for erythrocyte invasion by Plasmodium falciparum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

Malaria vaccine developments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

Iterative weighted regression analysis of logit responses: a computer program for analysis of bioassays and immunoassays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.01.005

10.1016/J.VACCINE.2006.01.005

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

16767804

1 reference

7 February 2018